

BILCARE GCS, INC.
FINANCIAL STATEMENTS
March 31, 2025 and 2024

BILCARE GCS, INC.
TABLE OF CONTENTS

	<u>Page</u>
INDEPENDENT ACCOUNTANTS' REVIEW REPORT	1 - 2
FINANCIAL STATEMENTS	
BALANCE SHEETS	3
STATEMENTS OF INCOME AND RETAINED EARNINGS	4
STATEMENTS OF CASH FLOWS	5
NOTES TO FINANCIAL STATEMENTS	6 - 9
SUPPLEMENTARY FINANCIAL INFORMATION	
EXHIBIT I - SCHEDULES OF OPERATING EXPENSES	10



Staff Ciampino & Company, P.C.

CERTIFIED PUBLIC ACCOUNTANTS

10 Colvin Avenue
Albany, New York 12206

518 459-9205 ♦ 800 724-6567
Facsimile: 518 459-1395

web: www.staffciampino.com
e-mail: info@staffciampino.com

INDEPENDENT ACCOUNTANTS' REVIEW REPORT

To the Board of Directors
Bilcare GCS, Inc.
Dover, Delaware

We have reviewed the accompanying financial statements of Bilcare GCS, Inc. (a Delaware corporation), which comprise the balance sheets as of March 31, 2025 and 2024, and the related statements of income and retained earnings and cash flows for the years then ended, and the related notes to the financial statements. A review includes primarily applying analytical procedures to management's financial data and making inquiries of company management. A review is substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements as a whole. Accordingly, we do not express such an opinion.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement whether due to fraud or error.

Accountants' Responsibility

Our responsibility is to conduct the review engagement in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. Those standards require us to perform procedures to obtain limited assurance as a basis for reporting whether we are aware of any material modifications that should be made to the financial statements for them to be in accordance with accounting principles generally accepted in the United States of America. We believe that the results of our procedures provide a reasonable basis for our conclusion.

We are required to be independent of Bilcare GCS, Inc. and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements related to our review.

Accountants' Conclusion

Based on our reviews, we are not aware of any material modifications that should be made to the accompanying financial statements in order for them to be in accordance with accounting principles generally accepted in the United States of America.

Supplementary Information

The accompanying supplementary information included in Exhibit I is presented for purposes of additional analysis and is not a required part of the basic financial statements. Such information is the responsibility of management and was derived from, and relates directly to, the underlying accounting and other records used to prepare the financial statements. The supplementary information has been subjected to the review procedures applied in our review of the basic financial statements. We are not aware of any material modifications that should be made to the supplementary information. We have not audited the supplementary information and do not express an opinion on such information.

Albany, New York
April 28, 2025

Staff Campion & Company, P.C.

BILCARE GCS, INC.
BALANCE SHEETS
March 31, 2025 and 2024

<u>ASSETS</u>		
	<u>2025</u>	<u>2024</u>
CURRENT ASSETS		
Cash	\$ 251,068	\$ 270,787
Accounts receivable	103,513	359,148
Prepaid expenses	868	868
Advances to vendors, less allowances for advances to vendors of \$ -0- and \$ -0-for 2025 and 2024, respectively.	<u>6,162</u>	<u>3,358</u>
Total current assets	<u>361,611</u>	<u>634,161</u>
OTHER ASSETS		
Deferred income tax asset	<u>21,982</u>	<u>-</u>
Total other assets	<u>21,982</u>	<u>-</u>
TOTAL ASSETS	<u>\$ 383,593</u>	<u>\$ 634,161</u>
 <u>LIABILITIES AND STOCKHOLDERS' EQUITY</u>		
	<u>2025</u>	<u>2024</u>
CURRENT LIABILITIES		
Accounts payable	\$ 80,400	\$ 199,163
Accrued expenses	9,500	33,929
Customer deposits	-	8,229
Income taxes payable	<u>1,000</u>	<u>16,869</u>
Total current liabilities	<u>90,900</u>	<u>258,190</u>
STOCKHOLDERS' EQUITY		
Common stock- 200 shares no par value authorized, 200 shares issued and outstanding at \$1 stated value	200	200
Retained earnings	<u>292,493</u>	<u>375,771</u>
Total stockholders' equity	<u>292,693</u>	<u>375,971</u>
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	<u>\$ 383,593</u>	<u>\$ 634,161</u>

See accompanying notes and independent accountants' review report.

BILCARE GCS, INC.
STATEMENTS OF INCOME AND RETAINED EARNINGS
For the Years Ended March 31, 2025 and 2024

	2025	%	2024	%
SALES	\$ 852,356	100.00	\$ 1,674,720	100.00
COST OF SALES				
Purchases	648,446	76.08	1,325,236	79.13
GROSS PROFIT	203,910	23.92	349,484	20.87
OPERATING EXPENSES	306,670	35.98	269,584	16.10
INCOME (LOSS) FROM OPERATIONS BEFORE INCOME TAXES	(102,760)	(12.06)	79,900	4.77
PROVISION FOR (BENEFIT FROM) INCOME TAXES	(19,482)	(2.29)	16,869	1.01
NET INCOME (LOSS)	(83,278)	(9.77)	63,031	3.76
RETAINED EARNINGS - BEGINNING OF YEAR	375,771		312,740	
RETAINED EARNINGS - END OF YEAR	\$ 292,493		\$ 375,771	

See accompanying notes and independent accountants' review report.

BILCARE GCS, INC.
STATEMENTS OF CASH FLOWS
For the Years Ended March 31, 2025 and 2024

	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES		
Net income (loss)	\$ (83,278)	\$ 63,031
Adjustments to reconcile net income (loss) to net cash provided (used) by operations:		
Deferred tax asset	(21,982)	-
(Increase) decrease in:		
Accounts receivable	255,635	1,479,574
Prepaid expenses	-	(74)
Advances to vendors	(2,804)	33,815
Increase (decrease) in:		
Accounts payable	(118,763)	(1,529,552)
Accrued expenses	(24,429)	(25,071)
Customer deposits	(8,229)	2,420
Income taxes payable	(15,869)	7,441
Net cash provided (used) by operating activities	(19,719)	31,584
NET INCREASE (DECREASE) IN CASH	(19,719)	31,584
CASH AT BEGINNING OF PERIOD	270,787	239,203
CASH AT END OF PERIOD	\$ 251,068	\$ 270,787

SUPPLEMENTAL DISCLOSURES

INCOME TAXES PAID		
Provision for (benefit from) income taxes per statements of income and retained earnings	\$ (19,482)	\$ 16,869
Adjustments related to income taxes payable	15,869	(7,441)
Adjustments related to deferred income taxes	21,982	-
TOTAL INCOME TAXES PAID	\$ 18,369	\$ 9,428

See accompanying notes and independent accountants' review report.

BILCARE GCS, INC.
NOTES TO FINANCIAL STATEMENTS
March 31, 2025 and 2024

(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of Bilcare GCS, Inc. (the "Company") is presented to assist in understanding the Company's financial statements. The financial statements and notes are representations of the Company's management who is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

NATURE OF OPERATIONS

Bilcare GCS, Inc. offers a full spectrum of services across the supply chain, from pre-formulation to global logistics and distribution, comparator procurement, depot management, clinical packaging and labeling. Regulatory and analytical services are some of the Company's critical areas of expertise. Bilcare GCS, Inc. partners with over 25 strategic GMP Compliant Depots across the globe. Bilcare GCS, Inc. implements some of the best storage and distribution practices in the Clinical Supply industry. The Company is a corporation that was organized and began business in Dover, Delaware on May 26, 2015.

USE OF ESTIMATES

The process of preparing financial statements in conformity with accounting principles generally accepted in the United States of America requires the use of estimates and assumptions that affect the recorded amounts of assets, liabilities, revenues and expenses. Such estimates primarily relate to unsettled transactions and events as of the date of the financial statements. Accordingly, upon settlement, actual results may differ from estimated amounts.

CASH AND CASH EQUIVALENTS

The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. There were no cash equivalents as of March 31, 2025 and 2024.

The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.

FOREIGN CURRENCY TRANSLATION

The functional currency of the Company is in U.S. dollars. Monetary assets and liabilities are all denominated in U.S. dollars. Expenses are translated at the exchange rates in effect at the date of the transaction. For the year ended March 31, 2025 the Company had realized translation gains of \$ 1,002 and losses of \$ 712. For the year ended March 31, 2024 the Company had realized translation gains of \$ 1,049 and losses of \$ 6,319. These translation gains and losses have been included in cost of goods sold.

ACCOUNTS RECEIVABLE

The balance in accounts receivable is considered by management to be fully collectible, and accordingly, no allowance for credit losses is required. If in the future, management determines that amounts may be uncollectible, an allowance will be established and operations will be charged when that determination is made. Bad debt expense totaled \$ 10,589 and \$ -0- for the years ended March 31, 2025 and 2024, respectively.

BILCARE GCS, INC.
NOTES TO FINANCIAL STATEMENTS
March 31, 2025 and 2024

(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

ALLOWANCES FOR CREDIT LOSSES

In June 2016, the FASB issued guidance (FASB ASC 326) which significantly changed how entities will measure credit losses for most financial assets and certain other instruments that aren't measured at fair value through net income. The most significant change in this standard is a shift from the incurred loss model to the expected loss model. Under the standard, disclosures are required to provide users of the financial statements with useful information in analyzing an entity's exposure to credit risk and the measurement of credit losses. Financial assets held by the company that are subject to the guidance in FASB ASC 326 were trade accounts receivable.

We adopted the standard effective April 1, 2023. The impact of the adoption was not considered material to the financial statements and primarily resulted in new/enhanced disclosures only.

ADVANCES TO VENDORS

The Company advances funds to certain vendors in the normal course of business for prepayment of goods. As of March 31, 2025 and 2024 the Company had advanced funds of \$ 6,162 and \$ 3,358, respectively.

INVENTORY

The Company's inventories are recorded at the lower of cost or net realizable value. There were no inventories on hand at March 31, 2025 and 2024.

INCOME TAXES

The provision for income taxes includes the tax effects of transactions reported in the financial statements and consists of taxes currently due or refundable plus deferred taxes. Deferred taxes are recognized for differences between the basis of assets and liabilities for financial statement and income tax purposes. These differences related primarily to operating loss tax benefits. The deferred tax assets and liabilities represent the future tax consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled.

REVENUE RECOGNITION

Sales are recognized when revenue is realized or becomes realizable and has been earned. In general, revenue is recognized when the earnings process is complete, which is upon shipment of products. The shipment of products is a single performance obligation and is satisfied at a point in time once the performance obligation is met.

The company has recognized the following pertaining to its revenue recognition policies:

	April 1, 2023	March 31, 2024	March 31, 2025
Accounts receivable	\$ 1,838,722	\$ 359,148	\$ 103,513
Advances to vendors	\$ 37,173	\$ 3,358	\$ 6,162
Customer deposits	\$ 5,809	\$ 8,229	\$ -0-

BILCARE GCS, INC.
NOTES TO FINANCIAL STATEMENTS
March 31, 2025 and 2024

(2) UNCERTAIN TAX POSITIONS

Management has determined that the Company does not have any uncertain tax positions and associated unrecognized benefits that materially impact the financial statements or related disclosures. Since tax matters are subject to some degree of uncertainty, there can be no assurance that the Company's tax returns will not be challenged by the taxing authorities and that the Company or its shareholders will not be subject to additional tax, penalties, and interest as result of such a challenge. Generally, the Company's tax returns remain open for three years for the federal income tax examination and various years for state taxing authorities.

(3) RELATED PARTY TRANSACTIONS

During the years ended March 31, 2025 and 2024, the Company incurred consulting fees of \$ -0- and \$ 100,000, respectively, to Bilcare Mauritius Limited (BML) and \$ 64,000 and \$ -0-, respectively, to Bilcare Pharma Solution Limited.

The Company has a Cost Sharing Agreement with Bilcare Limited and Bilcare GCS Ltd., UK. In line with said agreement, for the years ended March 31, 2025 and 2024, the Company has reimbursed Bilcare Limited in the amounts of \$ 237,885 and \$ 117,211, respectively as logistics cost reimbursement as well as \$ 25,090 and \$ -0- as management fees, respectively.

Included in accounts payable at March 31, 2025 and 2024, were amounts owed to Bilcare Limited of \$ 21,251 and \$ 61,424, respectively.

Included in accounts payable at March 31, 2025 and 2024, were amounts owed to Bilcare GCS Limited, UK of \$ -0- and \$ 952, respectively.

(4) INCOME TAXES

Federal and state income taxes are accrued at the end of each year in accordance with applicable income tax laws.

A summary of the income taxes reported in this statement is as follows:

	<u>2025</u>	<u>2024</u>
<u>Provision</u>		
Current		
Federal	\$ -0-	\$ 16,869
State	2,500	-0-
<u>Deferred</u>		
Federal	<u>(21,982)</u>	<u>-0-</u>
Total provision for (benefit from) income taxes	<u>\$ (19,482)</u>	<u>\$ 16,869</u>

The company has an operating loss carryforward for Federal income tax purposes of \$ 21,982. These carryforwards do not expire and are expected to be used in the near future.

BILCARE GCS, INC.
NOTES TO FINANCIAL STATEMENTS
March 31, 2025 and 2024

(5) STOCKHOLDERS' EQUITY

On May 26, 2015, the Company issued 100 shares of common stock, to the parent company, Bilcare Limited, in exchange for \$ 1,000 receivable.

On January 4, 2021, the above common stock was cancelled and the Company issued 200 new shares of common stock at \$ 1 stated value to Bilcare Mauritius Limited.

On December 18, 2023, the above common stock was transferred at face value by Bilcare Mauritius Limited (BML) to Bilcare Limited as part of the liquidation proceeds as BML has been liquidated through a shareholder's voluntary liquidation. There was no purchase consideration paid by Bilcare Limited. The above common stock was cancelled and the Company issued 200 new shares of common stock at \$ 1 stated value to Bilcare Limited.

(6) CONTINGENCIES

During the year ended March 31, 2017, the Company advanced funds to Spring Bio Solutions in the amount of \$ 468,050. The Company initiated litigation with Spring Bio Solutions in New York Courts due to the failure of Spring Bio Solutions to deliver the goods as promised. After exhausting all efforts through discussions with Spring Bio Solutions and through New York Courts, management made the determination that this amount is not collectible. Management had established an allowance for the full amount as of March 31, 2021. As of March 31, 2024 the case against Spring Bio Solutions in the New York Courts is closed as per the order of New York Court dated May 17, 2023. Therefore, both the allowance and the receivable from Spring Bio Solutions have been eliminated for the year ended March 31, 2024.

(7) COMPARATIVE FIGURES

Certain 2024 figures have been reclassified to conform with the 2025 presentation. These changes had no effect on prior year results of operations, financial position or cash flows.

(8) SUBSEQUENT EVENTS

Management considered and evaluated the nature of any subsequent events through April 28, 2025, which is the date that the financial statements were available to be issued, and believes there is nothing of significance to report.

SUPPLEMENTARY FINANCIAL INFORMATION

BILCARE GCS, INC.
SUPPLEMENTARY FINANCIAL INFORMATION
For the Years Ended March 31, 2025 and 2024

EXHIBIT I - SCHEDULES OF OPERATING EXPENSES

	2025	%	2024	%
Management fees	\$ 180,173	21.14	\$ 117,211	7.00
Professional fees	96,353	11.30	125,805	7.51
Bad debt expense	10,589	1.24	-	0.00
Travel	9,839	1.15	530	0.03
Bank service charges	5,075	0.60	8,579	0.51
Insurance expense	2,477	0.29	2,501	0.15
Seminars & conferences	1,581	0.19	-	0.00
Fines and penalties	583	0.07	430	0.03
Selling expenses	-	0.00	14,528	0.87
TOTAL OPERATING EXPENSES	<u>\$ 306,670</u>	<u>35.98</u>	<u>\$ 269,584</u>	<u>16.10</u>

See independent accountants' review report.